Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
| Revenue (TTM) | $1.27B |
| Gross Profit (TTM) | $719.30M |
| EBITDA | $-41.60M |
| Operating Margin | 14.90% |
| Return on Equity | -8.08% |
| Return on Assets | -1.92% |
| Revenue/Share (TTM) | $6.86 |
| Book Value | $6.35 |
| Price-to-Book | 2.92 |
| Price-to-Sales (TTM) | 2.92 |
| EV/Revenue | 2.283 |
| EV/EBITDA | 252.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 51.90% |
| Shares Outstanding | $194.49M |
| Float | $90.62M |
| % Insiders | 1.83% |
| % Institutions | 56.79% |
Volatility is currently contracting
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy Carvykti.
BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026.
Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy Real-world evidence and post-authorization safety study findings will also be presented BRIDGEWATER, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.
BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m.
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first quarter of company-wide profitability in its history.
Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company's first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call.
BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain as an advisor through August to support a smooth transition.
On July 15, J&J, a Legend Biotech Corporation partner, announced continued strong demand for Carvykti. Sales of this CAR-T cell therapy were $657 million in the second quarter, up 10.1% quarter-on-quarter and 49.7% year-on-year. Legend hasn't yet announced when it will publish its second-quarter report, but given Carvykti's sales, I expect it to beat consensus estimates.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LEGN and any ticker you trade — then tracks every position and per-strategy win rate.
